Global science, local innovation: In an interview with European Biotech Magazine, WuXi AppTec Co-CEO Steve Yang explains why Europe remains a key source of scientific innovation, why the company continues to expand its Munich site despite geopolitical tensions, and why trust, quality, and international collaboration are essential for the future of drug discovery.
ADC expert appointed as CEO
AppointmentsProfessor Andreas Pahl took over as Chief Executive Officer of Simris Biologics GmbH in mid-July. The subsidiary of Swedish Simris Group based in Berlin, develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies.
AstraZeneca reunites with Dizal in $1.5bn lung cancer deal
Latest NewsAstraZeneca has agreed to pay up to $1.5bn for global rights to Zegfrovy, an EGFR-targeted lung cancer drug developed by Dizal Pharmaceutical – the Chinese biotech it helped create nearly a decade ago.
Bayer rebuilds pharma while waiting for Monsanto relief
Background, Latest NewsA stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation.
WuXi AppTec bets on expansion in Europe
Background, Latest NewsGlobal science, local innovation: In an interview with European Biotech Magazine, WuXi AppTec Co-CEO Steve Yang explains why Europe remains a key source of scientific innovation, why the company continues to expand its Munich site despite geopolitical tensions, and why trust, quality, and international collaboration are essential for the future of drug discovery.
Seasoned CSO takes the helm
AppointmentsAriane de Ganck, PhD, took over the position as new Chief Scientific Officer (CSO) at Ardena. She started in 2019 at the Ghent-based CDMO/CRO.
Draig raises $65M Series B as depression trials advance
Latest NewsWelsh biotech Draig Therapeutics has raised an oversubscribed $65 million Series B to accelerate its neuropsychiatry pipeline, taking its total funding to $205 million little more than a year after emerging from stealth.
CriteriaCaixa targets €300M for biotech and tech by 2030
Latest NewsSpanish investment holding company CriteriaCaixa plans to invest €300m in early-stage biotechnology and technology companies by 2030 through its two specialist venture funds.
Targeted Protein Degradation: Designed to destroy
Background, Latest NewsTargeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting chimeras) has evolved into a broader “induced proximity” field that now includes molecular glue degraders, degrader-antibody conjugates (DACs), lysosome-targeting chimeras (LYTACs), RNA degraders and other proximity-based therapeutics.
PharmNovo raises €3.5M for phase 2 pain trial
Latest NewsSwedish biotech PharmNovo has raised about SEK39m (€3.5m) to help finance a phase 2 study of PN6047, its experimental treatment for neuropathic pain.
AB Science cuts three trials in pipeline reset
Latest NewsFrench biotech AB Science is discontinuing three masitinib trials as it concentrates its clinical resources on an ALS phase 3 programme and the early-stage development of AB8939 in acute myeloid leukaemia.